81 results
6-K
EX-99.1
IMMP
Immutep Limited
24 Apr 24
Immutep Announces Positive Preliminary Topline Results from
5:40pm
and neck cancer: molecular biology and ongoing challenges. Cell Death Dis 10, 540 (2019).
Johnson, D.E., Burtness, B., Leemans, C.R. et al. Head
6-K
EX-99.1
IMMP
Immutep Limited
9 Nov 23
Current report (foreign)
5:01pm
. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death … ).
Alsahafi, E., Begg, K., Amelio, I. et al. Clinical update on head and neck cancer: molecular biology and ongoing challenges. Cell Death Dis 10, 540
6-K
EX-99.1
IMMP
Immutep Limited
24 Oct 23
Current report (foreign)
6:35am
for approximately 80-85% of all lung cancers, impacting an estimated 1.87 million people annually, and is the highest cause of death among all cancers4-6
6-K
EX-99.1
IMMP
Immutep Limited
17 May 23
Immutep’s Efti in Combination with Pembrolizumab Achieves Excellent Initial
6:06am
1.87 million people annually, and is the highest cause of death among all cancers 1-3.
KEYTRUDA® is a registered trademark of Merck Sharp & Dohme LLC
6-K
EX-99.1
kh7bhekth33b
28 Apr 23
Immutep Quarterly Activities Report & Appendix 4C
6:10am
F-3
EX-3.1
x4qw11d5 cmnw84xkeij
28 Apr 23
Shelf registration (foreign)
6:09am
6-K
EX-99.1
5xf6qzy7nc 3a
11 Apr 23
Immutep Announces Changes to the Board
6:06am
6-K
EX-99.1
3cgiwtc8cw2jysgih
14 Nov 22
Current report (foreign)
10:04am
6-K
EX-99.1
yqwjutd1 hk2cgy
1 Sep 22
Preliminary final report
5:06pm
6-K
EX-99.1
o4k2hcskv5jffyd
28 Jul 22
Immutep Quarterly Activities Report & Appendix 4C
7:41pm
6-K
EX-99.1
kxjh9hmfu r5
18 Nov 21
Current report (foreign)
12:00am
6-K
EX-99.2
abfwrs
12 Nov 21
Immutep Announces Publication of AIPAC, TACTI-002 and TACTI-003 Abstracts
12:00am
6-K
EX-99.1
mtr6nzlw74arby
10 May 21
Immutep Operational Update
12:00am
6-K
EX-99.1
v121lkoi9rvc2t5 gk8
17 Mar 21
Current report (foreign)
12:00am
6-K
EX-99.1
ekuy63u8us
24 Feb 21
Half-Year Financial Report
12:00am
6-K
EX-99.1
1sn 2n8hq
28 Jan 21
Immutep Announces Advancement of Phase Ii Trial for Eftilagimod Alpha In COVID-19 Patients to Randomised Portion of the Study
12:00am
6-K
EX-99.1
4g01r nkn
11 Dec 20
Immutep Reports Statistically Significant Survival Benefit for Key
12:00am